METiS Pharmaceuticals and Eli Lilly Strike $1.1 Billion AI-LNP Delivery Platform Collaboration

METiS Pharmaceuticals (7666.HK) announced a strategic collaboration with Eli Lilly worth up to $1.1 billion in total, focused on developing LNP delivery solutions based on generative AI. METiS will use its NanoForge-driven AiLNP platform to develop next-generation delivery technologies, while Lilly contributes drug discovery, development and commercialization resources, aiming to support tissue-specific delivery across multiple therapeutic modalities.